Interleukin 18 as a Marker of Chronic Nephropathy in Children after Anticancer Treatment
Figure 1
(a) Concentrations of beta-2 microglobulin depending on treatment modality. (b) Concentrations of beta-2 microglobulin depending on clinical evidence of nephrotoxicity. (c) Concentrations of IL-18 depending on treatment modality. (d) Concentrations of IL-18 depending on clinical evidence of nephrotoxicity.
